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Abstract
Aims/Hypothesis: High fat diet (HFD)-induced insulin resistance (IR) is partially characterized by reduced skeletal muscle
mitochondrial function and peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC1a) expression. Our
previous study showed that a high dose of the bioflavonoid quercetin exacerbated HFD-induced IR; yet, others have
demonstrated that quercetin improves insulin sensitivity. The aim of this study was to investigate whether differing doses of
quercetin act in a time-dependent manner to attenuate HFD-induced IR in association with improved skeletal muscle
mitochondrial function and PGC1a expression.
Methods: C57BL/6J mice were fed HFD for 3 or 8 wks, with or without a low (50 ug/day; HF+50Q) or high (600 ug/day, HF+
600Q) dose of quercetin. Whole body and metabolic phenotypes and insulin sensitivity were assessed. Skeletal muscle
metabolomic analysis of acylcarnitines and PGC1a mRNA expression via qRT-PCR were measured.
Results: Quercetin at 50 ug/day for 8 wk attenuated HFD-induced increases in fat mass, body weight and IR and increased
PGC1a expression, whereas 600 ug/day of quercetin exacerbated fat mass accumulation without altering body weight, IR or
PGC1a. PGC1a expression correlated with acylcarnitine levels similarly in HF and HF+600Q; these correlations were not
present in HF+50Q. At both time points, energy expenditure increased in HF+50Q and decreased in HF+600Q, independent
of PGC1a and IR.
Conclusions/Interpretation: Chronic dietary quercetin supplementation at low but not higher dose ameliorates the
development of diet-induced IR while increasing PGC1a expression in muscle, suggesting that skeletal muscle may be an
important target for the insulin-sensitizing effects of a low dose of quercetin.
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PGC1a is downregulated in skeletal muscle by HFD and decreased
in skeletal muscle of type 2 diabetic individuals [6,13]. The
downregulation of PGC1a expression and mitochondrial function
in response to diet makes PGC1a an ideal target for the treatment
of obesity and type 2 diabetes.
Quercetin, a bioflavonoid abundant in apples, onions and tea, is
a powerful antioxidant that has the potential to improve insulin
action [14] and skeletal muscle mitochondrial biogenesis [15]. For
example, 6 wks of a quercetin diet (0.08% and 0.04%) significantly
reduced plasma glucose levels in obese, leptin receptor deficient
C57BL/KsJ-db/db mice [16] and improved hyperinsulinemia in
obese Zucker rats [17]. Dietary quercetin has also been shown to
increase skeletal muscle PGC1a and mitochondrial number [18].

Introduction
Reduced skeletal muscle mitochondrial function may play an
integral role in the onset of insulin resistance (IR) during dietinduced obesity [1–5]. Integration of dietary fat intake and
alterations in mitochondrial biogenesis and function are also
partially mediated by peroxisome proliferator receptor gamma
coactivator 1 alpha (PGC1a) expression [6–8]. PGC1a is a
transcriptional coactivator that coordinates gene expression from
the mitochondrial and nuclear genomes to change in mitochondrial number or function [9–11]. In skeletal muscle, PGC1a plays
an important role in fiber type switching to oxidative type 1 fibers
[12] and in promoting mitochondrial biogenesis [11]. Importantly,
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In contrast, we previously found that a higher dose of dietary
quercetin exacerbated HFD-induced IR while increasing long
chain but not short chain acylcarnitines, suggestive of incomplete
beta oxidation and may indicate reduced mitochondrial function
in skeletal muscle in C57BL6/J mice [19]. Given that others have
also found contradictory effects of quercetin, with seemingly
higher doses being detrimental to cellular systems [20–22], we
hypothesized that dietary quercetin supplementation acts in a
time- and dose-dependent manner to affect IR in association with
alterations in skeletal muscle PGC1a gene expression and
mitochondrial function. Consequently, we administered dietary
quercetin in a low or high dose in conjunction with a HFD and
examined phenotypic alterations, whole body insulin sensitivity
and metabolism. In addition, we determined whether quercetin
altered skeletal muscle PGC1a and acylcarnitine profiles in a timeand dose-dependent manner.

Methods
Animals
All experiments were reviewed and approved by the Pennington
Biomedical Research Center Institutional Animal Care and Use
Committee. Male C57BL/6J mice (N = 48) (stock number 000664,
Jackson Laboratory, Bar Harbor, ME, USA) were obtained and
weaned onto a low fat diet (10% kcal fat, Research Diets, New
Brunswick, NJ, USA). At 6 wks of age, mice (N = 16 per group)
were randomly assigned to one of the following diets (Research
Diets): 1. high fat (HF; 45% kcal fat; D12451), 2. high fat+high
dose of quercetin (HF+600Q; 45% kcal fat +600 ug/mouse/day;
D08072303) or high fat+low dose of quercetin (HF+50Q; 45%
kcal fat +50 ug/mouse/day; D08072305). All mice were singly
housed in shoebox cages with corncob bedding in controlled
environmental conditions (22uC) on a 12 hour light:dark cycle. At
3 wks and 8 wks after feeding respective diets, mice were

Figure 1. Body weight was measured weekly in mice fed a HFD (HF; black), HFD plus 50 ug/day quercetin (HF+50Q; gray) or a HFD
plus 600 ug/day of quercetin (HF+600Q; white) and is presented as means ± SEMs (A) and as the change in body weight over the
course of the study (B). (C) Weekly food intake was measured over a 48 h period and is shown as the average 24 h food consumption. Body
composition was assessed by NMR weekly and is reported as fat mass (D), lean body mass (E), percent fat (F) and percent lean body mass (G). All
values are reported as means 6 SEM. Significant differences between groups by a post hoc Tukey test is denoted by a difference in superscript.
doi:10.1371/journal.pone.0089365.g001
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Figure 2. Energy expenditure (A), physical activity (B) and respiratory exchange ratio (RER) (C) were measured by indirect
calorimetry in C57BL/6J mice after 3 wks of feeding respective diets. Gray bars represent night periods in A. Significant differences between
groups are denoted by differing superscripts. Insulin sensitivity was assessed by measuring blood glucose levels before and during an insulin
tolerance test after 3 wks on respective diets. Data are presented before, and at 15, 30, 60 and 120 mins after injection of insulin (D) and as the area
under the curve (AUC) for each treatment group (E). (F) Fasting blood glucose levels are also reported. All values are shown as the mean 6 SEM.
doi:10.1371/journal.pone.0089365.g002

exchange ratio (RER) was calculated from VCO2 and VO2.
Energy expenditure was calculated from VO2 and RER
measurements (VO2 X (3.815+ (1.23 X RER)) X 40.1868) and
expressed as kJ per kg body weight (BW) per hour (Flowmax,
Columbus Instruments, Columbus, OH, USA). Ambulatory and
total physical activity, measured by beam breaks, was also
obtained during this time.

euthanized and quadriceps muscle were harvested and snap frozen
in liquid nitrogen for measurement of gene expression or
metabolomic analysis.

Diets, Food Consumption and Phenotyping
Quercetin (Q0125) was purchased from Sigma Aldrich (St.
Louis, MO, USA) and HF+Q diets were cold processed by
Research Diets. All diets were stored at 4uC in light-protective,
airtight containers. Food was changed every 3 d and water was
provided ad libitum. Food consumption was assessed weekly by
weighing food before and after a 48 h period. Body weight and
composition (NMR Bruker Minispec, Billerica, MA, USA) were
measured weekly for the duration of the study. Percent fat and
percent (LBM) were calculated by dividing fat mass or LBM by
total body weight and multiplying by one hundred.

Insulin Sensitivity
Insulin sensitivity was assessed by insulin tolerance test (ITT)
and fasting blood glucose measurements. Mice were fasted for 4 h
and blood glucose was measured with a One Touch Basic
glucometer (Milpitas, CA, USA). After measuring fasting blood
glucose, mice were injected intraperitoneally with 0.75 U/kg BW
of insulin (NovolinR, Nordisk, Bagsvaerd, Denmark). Blood
glucose measurements were made 15, 30 60 and 120 minutes
following injection. Area under the curve (AUC) was calculated for
individual mice using GraphPad Prism 5.0 and averaged for each
treatment group.

Indirect Calorimetry
Energy expenditure (N = 8 per group) was evaluated at 3 wks
and 7 wks after feeding the respective diets. Mice were housed
individually in metabolic chambers (Oxymax Comprehensive Lab
Animal System; Columbus Instruments, Columbus, OH, USA) on
a 12 h light-dark cycle. After a 24 h acclimation period, the
volume of oxygen consumption (VO2) and volume of carbon
dioxide production (VCO2) was measured for 72 h. Respiratory
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Tri-Reagent (Molecular Research Center, Cincinnati, OH, USA)
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Figure 3. After 8 wks of feeding respective diets, energy expenditure (A), physical activity (B) and respiratory exchange ratio (RER)
(C) were measured by indirect calorimetry. Gray bars represent night periods in A. Insulin sensitivity was assessed by an insulin tolerance test
after 8 wks on respective diets and is shown as the average blood glucose levels before, and at 15, 30, 60 and 120 mins after injection of insulin (D)
and as the average area under the curve (AUC) for each treatment group (E). (F) Fasting blood glucose levels are also reported. All values are shown
as the mean 6 SEM. Significant differences between groups are denoted by differing superscripts.
doi:10.1371/journal.pone.0089365.g003

centrifuged. The muscle supernatant was stored at 280uC until
further analysis by tandem mass spectrometry on the SYNAPT
HDMS platform (Waters Corporation, Milford, MA, USA).

RNase-free DNase (Qiagen, Valencia, CA, USA). Degradation of
isolated RNA was prevented by addition of SUPERase-In
(Ambion, Austin, TX, USA). The quantity and quality of the
RNA was analyzed by spectrophotometry (ND-1000, NanoDrop
Technologies, Wilmington, DE, USA) and confirmed by gel
electrophoresis. RNA was reverse transcribed into a cDNA library
using M-MLV reverse transcriptase (Promega, Madison, WI,
USA). qRT-PCRwas performed using specific primers targeted
towards exon-exon junctions that were designed using PrimerExpress v2.0.0 software (Applied Biosystems, Foster City, CA,
USA). All samples were run in duplicate on the SmartCycler
platform (Cepheid, Sunnyvale, CA, USA). PGC1a gene expression
was analyzed using a standard curve and normalization to
cyclophilin B, an endogenous control.

Statistical Analysis
The data were analyzed with JMP statistical analysis software
and results are expressed as means 6 standard error. Body
composition parameters and glucose tolerance test (GTT) were
analyzed by repeated measures ANOVA. All other measurements
were analyzed by 3(diet) X 2(time point) ANOVA. A Tukey test
was used post hoc as necessary. A P value ,0.05 was used to
determine significance.

Results

Metabolomics

Whole Body Phenotypes

Tandem mass spectrometry analysis was used to evaluate
muscle extracts for 45 acylcarnitine (AC) species ranging from 2 to
20 carbons, in saturated and unsaturated forms as previously
described [19]. Briefly, protein extracts were prepared from tissues
extracted at the 4 wk and 8 wk time points at the zenith and nadir
of the metabolic cycle. Quadriceps muscle extracts were prepared
by pulverizing 50 mg of frozen tissue in liquid nitrogen, cold
ddH20 was added and the samples were homogenized on ice.
Samples were subjected to 1 freeze-fracture cycle, sonicated and

HF+50Q decreased BW compared to HF, whereas HF+600Q
showed no difference in BW compared to HF (Fig. 1A). By week 8
of the study, HF exhibited a 10.11 g increase in BW compared to
week 0, HF+50Q increased by 7.45 g and HF+600Q increased by
9.71 g (Fig. 1B). Despite significant differences in BW, there were
no significant differences in food consumption among the groups
any groups (Fig. 1C). Differences in BW between HF and HF+
50Q appeared to result predominantly from significant changes in
fat mass (Fig. 1D), with HF+50Q significantly decreasing fat mass
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Figure 4. Acylcarnitines were measured in quadriceps muscle after 3 wks (A) and 8 wks (B) in HF, HF+50Q and HF+600Q, and
pairwise correlation matrices were generated. Red represents a +1 correlation and blue a 21. Acylcarnitine species are named at the top of
each matrix, with the iteration of acylcarnitines occurring vertically.
doi:10.1371/journal.pone.0089365.g004

body insulin sensitivity at 8 wks when compared to HF (Fig. 3D);
whereas, the higher dose of quercetin had no effect on HFDinduced changes in insulin tolerance (Fig. 3E). Additionally, HF+
50Q but not HF+600Q experienced a decrease in plasma blood
glucose levels at 8 wks, although this decrease did not reach
statistical significance compared to HF but did when compared to
HF+600Q (Fig. 3F).

over the course of the 8 week supplementation period (Fig. 1D).
However, LBM was also decreased slightly but significantly in
HF+50Q compared to HF (Fig. 1E). Although BW was not
significantly different between HF and HF+600Q, there was a
significant increase in fat mass between the two groups, which
converged by the end of the 8 wk period (Fig. 1D). Likewise,
percent body fat was significantly lower in HF+50Q but higher in
HF+600Q (Fig. 1F); whereas, percent LBM was not different
between HF and HF+50Q but decreased in HF+600Q (Fig. 1G).

Acylcarnitines
Acylcarnitine species (45) were measured in skeletal muscle
tissue extracts from mice after 3 wks and 8 wks of feeding and are
presented in Table 1. Pairwise correlation matrices were generated
for all acylcarnitine levels within each treatment group and time
point. Surprisingly, given the changes in energy expenditure at
3 wks, there were relatively small differences in correlation
matrices between any groups at this time point (Fig. 4A). However,
the most notable difference in matrices appeared to occur between
HF and HF+600Q, with HF and HF+50Q being similar (Fig. 4A).
Both HF and HF+600Q but not HF+50Q experienced a decrease
in the number of strong positive correlations between medium
chain species (Fig. 4A). Additionally, HF+600Q exhibited fewer
strong positive and more negative correlations between long and
short chain species (Fig. 4A). However, by 8 wks of supplementation strong positive correlations that were present between long
and medium chain acylcarnitines were diminished in all treatment
groups compared to correlations seen at 3 wks (Fig. 4A and B). In

Metabolic Phenotype and Insulin Sensitivity
Metabolic phenotype was assessed in all groups of mice after
3 wks and 7 wks on the diets. At 3 wks, energy expenditure was
significantly increased in HF+50Q but decreased in HF+600Q
compared to HF (Fig. 2A) (Table S1), despite no differences in
physical activity among the groups (Fig. 2B). HF+600Q significantly decreased RER, indicating a greater reliance on fatty acid
as a metabolic substrate in this group, whereas the lower dose of
had no effect on RER (Fig. 2C). In addition, there were no
differences among groups at 3 wks in whole body insulin
sensitivity, assessed by ITT (Fig. 2D and E) or fasting blood
glucose levels (Fig. 2F).
The pattern of effects due to dietary quercetin supplementation
on energy expenditure, activity levels and RER remained constant
from 3 wk to 8 wks (Fig. 3A–C) (Table S1). However, the ITT
showed that the low dose of quercetin was able to improve whole
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Table 1. Acylcarnitines.

Acylcarnitine
CN

C2

C3

C4

C5

C4-OH

C5-OH

Time

HF

HF+50Q

HF+600Q

3 wk

2.46457060.359200

2.14159560.314587

2.19898160.417009

8 wk

2.89108060.339958

2.97434060.403685

2.66978360.283541

3 wk

2.30321060.276210

2.10760560.313589

2.27870060.402551

8 wk

3.27506060.398258

3.32507560.429395

3.25008360.335423

3 wk

0.01043560.001668

0.00892060.002155

0.01135060.001360

8 wk

0.01270760.002138

0.01173560.002724

0.01160660.002299

3 wk

0.06793560.005913

0.07312060.012329

0.05651360.007517

8 wk

0.09298560.011244

0.07939060.010965

0.07632860.007917

3 wk

0.01197060.001327

0.01727060.004532

0.00996360.002122

8 wk

0.02183360.005936

0.02017060.004247

0.01995660.003415

3 wk

0.03658060.006009

0.02823560.004595

0.03058860.006332

8 wk

0.04549860.006922

0.03591560.004305

0.03595060.005033

3 wk

0.02452060.003348

0.02021060.002669

0.01955060.003352

8 wk

0.02542560.003120

0.02900560.003885

0.02327260.002862

3 wk

0.01313560.001653

0.01219060.002626

0.01398160.002639

8 wk

0.02495560.004453

0.02051560.003324

0.02272260.004376

C6:1

3 wk

0.00210060.000310

0.00185560.000193

0.003175±0.000291*

8 wk

0.00254060.000331

0.00251560.000373

0.004389±0.000542*

C6

3 wk

0.01211060.001450

0.00923560.001258

0.00838860.001137

8 wk

0.01555860.001415

0.01392060.001773

0.010344±0.000972

3 wk

0.00057060.000304

0.00060060.000201

0.00041360.000188

C4-DC/Ci4-DC

C6-OH

8 wk

0.00087860.000187

0.00156060.000518

0.00392260.003378

C6-DC

3 wk

0.00126560.000307

0.00084560.000217

0.00051360.000099

8 wk

0.00082060.000158

0.00071060.000247

0.00065660.000083

C7

3 wk

0.00001060.000010

0.00000060.000000

0.00000060.000000

8 wk

0.00000060.000000

0.00000060.000000

0.00027260.000272

C8-1

C8

C8:1-OH/C9

3 wk

0.00475060.000326

0.00536060.000287

0.007044±0.000435*

8 wk

0.00565260.000361

0.00645060.000418

0.008622±0.000483*
0.00218860.000581

3 wk

0.00261060.000840

0.00252560.000854

8 wk

0.00445560.000862

0.00543560.000948

0.002628±0.000615

3 wk

0.00010060.000052

0.00010060.000100

0.00008160.000063

8 wk

0.00007560.000056

0.00006060.000028

0.00006760.000045

C3-DC/C8-OH

3 wk

0.01038060.001547

0.00768060.001333

0.00918160.001631

8 wk

0.01375060.001657

0.01331060.001911

0.01441160.002379

C10-3

3 wk

0.00075560.000643

0.00025060.000244

0.00015060.000063

8 wk

0.00004060.000040

0.00006560.000043

0.00016760.000113

C10:1

3 wk

0.00304060.000405

0.00348560.000234

0.004631±0.000366*

8 wk

0.00387860.000147

0.00379060.000313

0.004606±0.000293

C10

C10:1-OH

3 wk

0.00130560.000335

0.00155560.000430

0.00120660.000345

8 wk

0.00093860.000442

0.00060060.000281

0.00047260.000255

3 wk

0.00000060.000000

0.00001060.000010

0.00000060.000000

8 wk

0.00001560.000015

0.00004060.000018

0.00005060.000035

C10-OH/C5-DC

3 wk

0.00218560.000391

0.00148560.000352

0.00159460.000348

8 wk

0.00352060.000526

0.00305560.000386

0.00276160.000606

C12:1

3 wk

0.00411060.000117

0.00412560.000140

0.004919±0.000259*

8 wk

0.00412760.000159

0.00409060.000141

0.004772±0.000156*

C12/C6:1-DC

C12:1-OH

3 wk

0.00153060.000128

0.00131560.000236

0.00115060.000254

8 wk

0.00096860.000215

0.00112060.000333

0.00080060.000315

3 wk

0.00025560.000089

0.00015060.000067

0.00005660.000032
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Table 1. Cont.

Acylcarnitine

C12-0H/C7-DC

Time

HF

HF+50Q

HF+600Q

8 wk

0.00051060.000170

0.00037060.000091

0.00041160.000195

3 wk

0.00189560.000423

0.00100560.000329

0.00134460.000376

8 wk

0.00287760.000410

0.00237060.000415

0.00240060.000589

C12-DC

3 wk

0.00207560.000481

0.00207560.000333

0.00182560.000422

8 wk

0.00341860.000668

0.00455060.000922

0.00396160.001000

C14-2

3 wk

0.00038560.000115

0.00034560.000204

0.00024460.000089

8 wk

0.00031760.000091

0.00038060.000136

0.00021760.000084

C14-1

3 wk

0.00223560.000202

0.00187060.000370

0.00139460.000360

8 wk

0.00251360.000453

0.00240560.000570

0.00119460.000388

3 wk

0.00464560.000860

0.00357060.000536

0.00260660.000538

8 wk

0.00628360.001052

0.00747060.001169

0.00450060.001135

3 wk

0.00001060.000010

0.00002060.000015

0.00001360.000013

8 wk

0.00000060.000000

0.00001060.000010

0.00003960.000022

3 wk

0.00225060.000449

0.00118060.000398

0.00125660.000281

8 wk

0.00409060.000545

0.00308060.000510

0.00297860.000681

3 wk

0.00199060.000292

0.00115060.000288

0.00134460.000249

8 wk

0.00301760.000353

0.00279560.000328

0.00257860.000465

C14/C8:1-DC

C8-DC

C14-1-OH

C14-OH

C14:2-DC

C14-DC

C16:2

C16-1

C16/C10:1-DC

C10-DC

C16:1-OH

C16-OH

C16-DC

C18-2

C18-1

C18/C12-1-DC

C18:2-OH

C18-1-OH

C18-OH

C18:1-DC

3 wk

0.00161060.000365

0.00071060.000204

0.00096960.000300

8 wk

0.00213060.000609

0.00222560.000491

0.00177860.000236

3 wk

0.00016560.000071

0.00010060.000032

0.00010060.000033

8 wk

0.00013060.000033

0.00033060.000074

0.00036160.000125

3 wk

0.00242560.000463

0.00192060.000493

0.00181960.000399

8 wk

0.00354060.000544

0.00459060.000580

0.00292860.000547

3 wk

0.00580060.001428

0.00472060.001111

0.00297560.000566

8 wk

0.00788060.001334

0.01019060.001743

0.00591760.001124

3 wk

0.02538560.007684

0.01908060.005025

0.01161360.002322

8 wk

0.03025560.005623

0.04622060.007572

0.03299460.009475

3 wk

0.01526060.005301

0.01642560.004833

0.01211960.004124

8 wk

0.01172060.006513

0.028035±0.004823*

0.01131160.002841

3 wk

0.00247560.000417

0.00182060.000470

0.00187560.000344

8 wk

0.00384360.000466

0.00402560.000622

0.00352260.000567

3 wk

0.00194560.000381

0.00137560.000430

0.00150060.000283

8 wk

0.00331260.000560

0.00402560.000663

0.00350660.000553

3 wk

0.00000060.000000

0.00000060.000000

0.00000660.000006

8 wk

0.00000060.000000

0.00001560.000011

0.00000060.000000

3 wk

0.00679560.001936

0.00721060.002701

0.00376960.000786

8 wk

0.00756560.001419

0.011500±0.001968

0.00611160.001312

3 wk

0.02401560.006711

0.02094560.006635

0.01210060.002595

8 wk

0.02934060.005812

0.04249560.007508

0.02739460.006660

3 wk

0.01395560.002666

0.01136060.002363

0.00927560.001488

8 wk

0.01810760.003024

0.02521060.003960

0.02032860.004892

3 wk

0.00176560.000283

0.00155560.000535

0.00143860.000247

8 wk

0.00279860.000407

0.00300060.000468

0.00252260.000320

3wk

0.00310060.000625

0.00265060.000715

0.00210060.000533

8 wk

0.00545060.000885

0.00596060.000978

0.00507860.000960

3wk

0.00072560.000140

0.00061560.000191

0.00063160.000173

8 wk

0.00156560.000296

0.00195060.000342

0.00142260.000251

3 wk

0.00003560.000017

0.00008560.000026

0.00005660.000018

8 wk

0.00003060.000021

0.00005060.000020

0.00003960.000027
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Table 1. Cont.

Acylcarnitine
C18-DC

C20:4

C20/C14:1-DC

C20-OH

C22/C16:1-DC

Time

HF

HF+50Q

HF+600Q
0.00006960.000025

3 wk

0.00005560.000014

0.00003060.000020

8 wk

0.00001560.000008

0.000080±0.000019*

0.00005660.000021

3 wk

0.00020560.000126

0.00020060.000092

0.00023860.000148

8 wk

0.00023760.000064

0.000570±0.000179

0.00020660.000083

3 wk

0.00118560.000258

0.00075560.000234

0.00066960.000158

8 wk

0.00143860.000348

0.00179560.000345

0.00190060.000526

3 wk

0.00006560.000029

0.00003560.000018

0.00001360.000013

8 wk

0.00008860.000027

0.00010060.000029

0.00006160.000022

3 wk

0.00000560.000005

0.00000560.000005

0.00001960.000019

8 wk

0.00001360.000013

0.00002060.000013

0.000094±0.000039*

Acylcarnitine values are shown in mM.
*denotes a significant difference (P,0.05) from HF by post hoc Tukey test. Significantly different and trending (P,0.081) values from HF are bolded.
doi:10.1371/journal.pone.0089365.t001

both HF and HF+600Q, there were more negative correlations
present between long and medium and long and short chain
species. When comparing acylcarnitine correlations across time,
the low dose of quercetin supplementation prevented weakening of
these positive correlations from 3 wks to 8 wks, specifically those
between the long and short chain acylcarnitines (Fig. 4A and B),
the high dose of quercetin supplementation exaggerated the
number of strong correlations between acylcarnitine species being
reversed or diminished compared to HF alone (Fig. 4A and B).
Consistent with the correlation matrices results, we observed
several significantly increased acylcarnitine species in HF+600Q
compared to HF, including C8-1, C10:1 and C12:1, but no
differences between HF and HF+50Q at 3wks (Table 1). At 8wks,
these differences between HF and HF+600Q remained in all
species except C10:1 (Table 1). Additionally, HF+600Q showed
significant increases in C6:1 and C22/C16:1-DC compared to HF
and HF+50Q (Table 1). HF+50Q experienced significant differences compared to both HF and HF+600Q in medium and
long chain acylcarnitine species, increasing in C10-DC compared
to HF and HF+600Q and in C18-DC compared to HF but not
HF+600Q (Table 1). Several other species also showed trends in
changes between groups (P,0.081), including a decrease in C6
and C8 and an increase in C10:1 in HF+600Q compared to HF
and HF+50Q and an increase in C18-2 and C20:4 in HF+50Q
compared to both HF and HF+600Q.

acylcarnitines with PGC1a expression among dietary groups at
3wks, HF and HF+50Q showed similar correlation patterns in
short and long chain species, and HF and HF+600Q showed
similar correlation patterns in medium chain species (Fig. 5C).
Interestingly, the strong positive correlations between PGC1a and
acylcarnitines revealed at 3wks in HF were almost totally reversed
by 8wks of feeding to produce negative correlations (Fig. 5C). This
reversal was exacerbated in the HF+600Q group, specifically in
the long and medium chains (Fig. 5C). Yet, consistent with the
insulin sensitizing effects of the low quercetin dose, HF+50Q
maintained a similar level and strength in most positive
correlations in all chain lengths at 8wks as that seen in the same
group at 3wks (Fig. 5C).

Discussion
Our previous work shows that a high dose of quercetin (24 mg/
day) in conjunction with a HFD exacerbates whole body IR after
3wks of feeding, and this alteration is abolished after 8wks of
supplementation [19]. However, others have shown a beneficial
effect of quercetin at lower doses, ranging from 0.8 mg/day to
7.2 mg/day and after 7 days to 10wks of supplementation in
rodents [17,23,24]. The insulin sensitizing effects of quercetin have
been tested in several rodent models, including streptozocininduced diabetic rats and genetic mouse models of impaired leptin
signaling, db/db and ob/ob mice [17,23–25]. Yet, it is important
to note that the development of IR and type 2 diabetes in humans
is due mostly to environmental conditions, such as low physical
activity and HFD [26,27]. Although our preliminary study in
HFD-induced obese C57BL/6J mice showed that quercetin
supplementation exaggerated IR [19], our previous results were
based on supplementation of quercetin at a level at least 3 times
higher than other groups [17,19,23–25]. Thus, the conflict of our
findings with other reports suggests that quercetin may act in a
time- and dose-dependent manner to affect insulin sensitization.
Several factors contribute to the pathogenesis of HFD-induced
IR and, in one case, HFD-induced IR occurs independent of
decreases in skeletal muscle mitochondrial function [28]. HFDinduced decreases in energy expenditure and skeletal muscle
mitochondrial function may play an important and causative role
in the onset of IR and type 2 diabetes [29]. This study
demonstrates that 3wks of 50 ug/day of dietary quercetin
supplementation increases energy expenditure without altering

PGC1a Expression
PGC1a mRNA expression was measured in skeletal muscle after
3wks and 8wks of in all treatment groups. There were no
differences in PGC1a mRNA expression among the groups at 3wks
(Fig. 5A). However, at 8wks, the lowest dose of quercetin was able
to significantly increase PGC1a mRNA expression compared to
HFD (Fig. 5B). Although the high dose of quercetin decreased
PGC1a at 8wks compared to HF, this decrease was not statistically
significant (Fig. 5B). The strongest correlations were seen between
PGC1a and short, medium, and long acylcarnitines in the HF
group compared to the others (Fig. 5C). HF+50Q maintained a
strong relationship between PGC1a and short chain acylcarnitines,
but decreased the strength of correlations with long and medium
chain acylcarnitines to PGC1a expression when compared to HF
(Fig. 5C). HF+600Q exhibited even further decreases in correlation strength or no correlation in all chain lengths with PGC1a
expression (Fig. 5C). When comparing correlation matrices of
PLOS ONE | www.plosone.org
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Figure 5. PGC1a mRNA was quantified by qRT-PCR after 3wks (A) and 8wks (B) of feeding respective diets and is shown as means ±
SEMs in arbitrary units (AU) for each group. Significant differences by Tukey post hoc are denoted by differing superscripts. (C) PGC1a mRNA
levels were correlated with acylcarnitine levels in each group after 3 and 8wks of feeding in HF, HF+50Q or HF+600Q. 21 correlations between gene
expression and an acylcarnitine is represented by blue and +1 correlations by red.
doi:10.1371/journal.pone.0089365.g005

exhibit IR during the onset of type 2 diabetes [5,30]. The
expression of PGC1a is a main determinant of mitochondrial
number and function in skeletal muscle in response to environmental stimuli such as dietary inputs [9,10]. In PGC1a knockout
mice, skeletal muscle mitochondrial function is decreased [31]; yet,
the mice exhibit increased oxygen consumption, indicative of
increased whole body energy expenditure [32]. In the present
study, 3wks of a low dose of quercetin increased energy
expenditure in the absence of changes in PGC1a expression and
mitochondrial function. The short term quercetin-induced increases in whole body energy expenditure that precede observed
differences in skeletal muscle PGC1a expression and mitochondrial
function and whole body insulin sensitivity improvements may be

BW or composition. After 8wks of supplementation, this lower
dose of quercetin attenuates HFD-induced IR, improves BW and
fat gain, maintains increased energy expenditure and improves
skeletal muscle mitochondrial function. Conversely, 3wks of
quercetin supplementation at 600 ug/day causes the opposite
effect, decreasing energy expenditure and slightly altering the
acylcarnitine correlation matrix, which is indicative of incomplete
beta oxidation. By 8wks of supplementation, this higher dose
exacerbates the skeletal muscle incomplete beta oxidation caused
by the HFD, maintains decreased energy expenditure and was
unable to ameliorate the HFD-induced IR.
HFD decreases PGC1a expression in several tissues, including
skeletal muscle [6,13], which is one of the primary tissues to
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due to the pleiotropic effects of quercetin on other tissues, such as
liver and adipose [25,33]. We speculate that, during quercetin
supplementation, the lack of coincidence of energy expenditure
alterations with insulin sensitivity may also suggest that whole body
insulin sensitivity is not likely driven by alterations in whole body
energy expenditure alone. Alternatively, changes in energy
expenditure may not be sufficient to cause alterations in insulin
sensitivity given that alterations in energy expenditure did not
result in a change in BW and fat accumulation at the 3wk time
point even though food intake was similar between all groups.
Quercetin-induced skeletal muscle PGC1a expression increases
only after longer supplementation (8wks) of a lower dose (50 ug/
day) of supplementation in the present study. This increase
parallels changes in acylcarnitine correlation matrices, which show
the relationships between acylcarnitine levels and provide us with
information on beta oxidation and mitochondrial function. Strong
correlations between acylcarnitines within the matrices indicate
complete beta oxidation; whereas, reciprocal associations between
short and long chain species reflect incomplete beta oxidation that
is indicative of reduced mitochondrial function [4,34]. Thus, the
strong positive correlations still present in HF+50Q after 8wks of
supplementation but not in HF or HF+600Q, indicate perseverance of mitochondrial function in this group alone. Improved
skeletal muscle mitochondrial function coupled with the upregulation of PGC1a and increases in whole body insulin sensitivity
suggest that quercetin-induced PGC1a expression in skeletal
muscle may play an important role in determining mitochondrial
function and insulin sensitivity. This is supported by the previous
report showing that PGC1a overexpression in skeletal muscle
improves whole body insulin sensitivity by increasing skeletal
muscle insulin sensitivity [35], which may be due to changes in
skeletal muscle mitochondrial function. Indeed, we show that
PGC1a expression highly and positively correlates with acylcarnitine levels in skeletal muscle in mice at 3wks, before differences in
insulin sensitivity or PGC1a expression levels are observed. Our
observed correlations may indicate that PGC1a expression levels
may drive quercetin-induced alterations in mitochondrial function
in skeletal muscle [8–12,36], which is recapitulated by quercetininduced changes in acylcarnitine levels [4,37,38]. This finding is
reinforced by the lack of positive correlations observed by 8wks in

HF and HF+600Q, in which PGC1a levels are similar to in HF
and decreased in HF+600Q compared to 3wk PGC1a values and
where incomplete beta oxidation is apparent via pairwise
correlation matrices [4,37,39,40]. Under low dose conditions
where quercetin increased PGC1a expression in the skeletal muscle
at 8wks, strong positive correlations were maintained between
PGC1a expression and acylcarnitine levels despite consumption of
the HFD. This upregulation and relationship coincided with
maintenance of mitochondrial function, suggesting that 8wks of
low dietary quercetin supplementation is sufficient to improve
skeletal muscle mitochondrial function through increasing PGC1a
expression.
In summary, our study demonstrated that the insulin sensitizing
effects of dietary quercetin supplementation occur in a time- and
dose-dependent manner. The protective benefits of quercetin in
preventing HFD-induced IR occurred only with a low dose of
quercetin after a longer supplementation period and were
associated with increased skeletal muscle PGC1a expression and
more complete beta oxidation. However, it appeared that
quercetin-induced increases in energy expenditure alone were
not sufficient to improve insulin sensitivity. We therefore propose
that low, chronic dietary quercetin supplementation can attenuate
diet-induced IR and improve skeletal muscle mitochondrial
function presumably via upregulation of skeletal muscle PGC1a.

Supporting Information
Table S1 Energy Expenditure Means.

(DOCX)

Acknowledgments
We would like to thank Michael Pellizzon, Ph.D (Research Diets) for his
expertise in the quercetin diet formulation.

Author Contributions
Conceived and designed the experiments: TMH LKS TWG. Performed
the experiments: TMH NRL LKS. Analyzed the data: TMH LKS TWG.
Contributed reagents/materials/analysis tools: TMH LKS TWG. Wrote
the paper: TMH LKS NRL TWG.

References
11. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, et al. (1999)
Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the
Thermogenic Coactivator PGC-1. Cell 98: 115–124.
12. Lin J, Wu H, Tarr PT, Zhang C-Y, Wu Z, et al. (2002) Transcriptional coactivator PGC-1[alpha] drives the formation of slow-twitch muscle fibres.
Nature 418: 797–801.
13. Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, et al. (2005) A high-fat
diet coordinately downregulates genes required for mitochondrial oxidative
phosphorylation in skeletal muscle. Diabetes 54: 1926–1933.
14. Anhe GF, Okamoto MM, Kinote A, Sollon C, Lellis-Santos C, et al. (2012)
Quercetin decreases inflammatory response and increases insulin action in
skeletal muscle of ob/ob mice and in L6 myotubes. Eur J Pharmacol 689: 285–
293.
15. Davis JM, Murphy EA, Carmichael MD, Davis B (2009) Quercetin increases
brain and muscle mitochondrial biogenesis and exercise tolerance. Am J Physiol
Regul Integr Comp Physiol 296: R1071–1077.
16. Jeong SM, Kang MJ, Choi HN, Kim JH, Kim JI (2012) Quercetin ameliorates
hyperglycemia and dyslipidemia and improves antioxidant status in type 2
diabetic db/db mice. Nutr Res Pract 6: 201–207.
17. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M (2008) Quercetin
Ameliorates Metabolic Syndrome and Improves the Inflammatory Status in
Obese Zucker Rats. Obesity 16: 2081–2087.
18. Davis JM, Murphy EA, Carmichael MD, Davis B (2009) Quercetin increases
brain and muscle mitochondrial biogenesis and exercise tolerance. American
Journal of Physiology - Regulatory, Integrative and Comparative Physiology
296: R1071–R1077.
19. Stewart L, Wang Z, Ribnicky D, Soileau J, Cefalu W, et al. (2009) Failure of
dietary quercetin to alter the temporal progression of insulin resistance among

1. Bournat JC, Brown CW (2010) Mitochondrial dysfunction in obesity. Current
Opinion in Endocrinology, Diabetes and Obesity 17: 446–452 410.1097/
MED.1090b1013e32833c33026.
2. Højlund K, Mogensen M, Sahlin K, Beck-Nielsen H (2008) Mitochondrial
Dysfunction in Type 2 Diabetes and Obesity. Endocrinology & Metabolism
Clinics of North America 37: 713–731.
3. Kim JA, Wei Y, Sowers JR (2008) Role of mitochondrial dysfunction in insulin
resistance. Circ Res 102: 401–414.
4. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008)
Mitochondrial Overload and Incomplete Fatty Acid Oxidation Contribute to
Skeletal Muscle Insulin Resistance. Cell Metabolism 7: 45–56.
5. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, et al. (1991)
Development of muscle insulin resistance after liver insulin resistance in high-fatfed rats. Diabetes 40: 1397–1403.
6. Crunkhorn S, Dearie F, Mantzoros C, Gami H, da Silva WS, et al. (2007)
Peroxisome Proliferator Activator Receptor c Coactivator-1 Expression Is
Reduced in Obesity. Journal of Biological Chemistry 282: 15439–15450.
7. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, et al. (2007) Metabolic
control of muscle mitochondrial function and fatty acid oxidation through
SIRT1/PGC-1alpha. Embo J 26: 1913–1923.
8. Koves TR, Li P, An J, Akimoto T, Slentz D, et al. (2005) Peroxisome
proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic
remodeling of skeletal myocytes mimics exercise training and reverses lipidinduced mitochondrial inefficiency. J Biol Chem 280: 33588–33598.
9. Knutti D, Kralli A (2001) PGC-1, a versatile coactivator. Trends in
Endocrinology & Metabolism 12: 360–365.
10. Liang H, Ward WF (2006) PGC-1a: a key regulator of energy metabolism.
Advances in Physiology Education 30: 145–151.

PLOS ONE | www.plosone.org

10

February 2014 | Volume 9 | Issue 2 | e89365

Quercetin and Mitochondrial Function

20.

21.

22.

23.

24.

25.

26.

27.
28.

29.

tissues of C57BL/6J mice during the development of diet-induced obesity.
Diabetologia 52: 514–523.
Metodiewa D, Jaiswal AK, Cenas N, Dickancaite E, Segura-Aguilar J (1999)
Quercetin may act as a cytotoxic prooxidant after its metabolic activation to
semiquinone and quinoidal product. Free Radic Biol Med 26: 107–116.
Watjen W, Michels G, Steffan B, Niering P, Chovolou Y, et al. (2005) Low
concentrations of flavonoids are protective in rat H4IIE cells whereas high
concentrations cause DNA damage and apoptosis. J Nutr 135: 525–531.
Ortega R, Garcı́a N (2009) The flavonoid quercetin induces changes in
mitochondrial permeability by inhibiting adenine nucleotide translocase. Journal
of Bioenergetics and Biomembranes 41: 41–47.
Vessal M, Hemmati M, Vasei M (2003) Antidiabetic effects of quercetin in
streptozocin-induced diabetic rats. Comp Biochem Physiol C Toxicol Pharmacol 135C: 357–364.
Jeong S-M, Kang M-J, Choi H-N, Kim J-H, Kim J-I (2012) Quercetin
ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in
type 2 diabetic db/db mice. Nutr Res Pract 6: 201–207.
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